Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Deloitte
McKinsey
Accenture
Harvard Business School
Citi
Mallinckrodt
US Army
Fuji

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,614,520

« Back to Dashboard

Which drugs does patent 5,614,520 protect, and when does it expire?

Patent 5,614,520 protects ULORIC and is included in one NDA.

This patent has fifteen patent family members in twelve countries.
Summary for Patent: 5,614,520
Title: 2-arylthiazole derivatives and pharmaceutical composition thereof
Abstract:Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): ##STR1## wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.
Inventor(s): Kondo; Shiro (Hachioji, JP), Fukushima; Hisashi (Hino, JP), Hasegawa; Masaichi (Hino, JP), Tsuchimoto; Masahiro (Hino, JP), Nagata; Ikuo (Hino, JP), Osada; Yoshio (Hino, JP), Komoriya; Keiji (Hachioji, JP), Yamaguchi; Hisao (Hino, JP)
Assignee: Teijin Limited (Osaka, JP)
Application Number:08/380,214
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,614,520
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,614,520

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y Y CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA ➤ Sign Up
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,614,520

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2-330147Nov 30, 1990
Japan3-216586Aug 02, 1991

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Boehringer Ingelheim
McKesson
Chinese Patent Office
Moodys
Fish and Richardson
Deloitte
Federal Trade Commission
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.